Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Gazprom Energoholding is not considering the purchase of TGC-1 shares from Fortum

12/11/23 TGKA

Kamaz intends to increase sales to 60 thousand trucks by 2030

12/11/23 KMAZ

Sberbank reported for 11 months of 2023 by RAS

12/11/23 SBER

Polymetal shareholders approve share swap for Russian holders

12/11/23 POLY

Severstal has found a supplier of equipment for pellet production

12/8/23 CHMF

Yandex became one of the world leaders in the field of AI development

12/8/23 YNDX

Kamaz shared its plans for 2024

12/8/23 KMAZ

MTS launched beta testing of Nuum video platform

12/8/23 MTSS

VTB decided to become an oil trader

12/8/23 VTBR

VK gets acquainted with the Belarusian IT community

12/8/23 VKCO